Originally published June 16, 2016 in PLoS ONE 11(6): e0157602
By Daniel A. Monti, George Zabrecky, Daniel Kremens, Tsao-Wei Liang, Nancy A. Wintering, Jingli Cai, Xiatao Wei, Anthony J. Bazzan, Li Zhong, Brendan Bowen, Charles M. Intenzo, Lorraine Iacovitti, Andrew B. Newberg
Abstract
Backgound
The purpose of this study was to assess the biological and clinical effects of n-acetyl-cysteine (NAC) in Parkinson’s disease (PD).
PICTURE: Pre and post NAC DaTscans (left and right respectively) from one particularly responsive patient shows a substantial increase in dopamine transporter binding in the basal ganglia (arrows).